[HTML][HTML] Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin–A Phase 2 Registry Study
A Khatami, G Sistani, DEK Sutherland… - Current …, 2022 - ncbi.nlm.nih.gov
Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
[PDF][PDF] Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Ad-ministered Activity Protocol in NETs of Variable Origin–A Phase 2 Reg-istry Study
A Khatami, G Sistani, DEK Sutherland… - researchgate.net
Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin - A Phase 2 Registry Study.
A Khatami, G Sistani, DEK Sutherland… - Current …, 2022 - europepmc.org
Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity
Protocol in NETs of Variable Origin - A Phase 2 Registry Study. - Abstract - Europe PMC Sign in …
Protocol in NETs of Variable Origin - A Phase 2 Registry Study. - Abstract - Europe PMC Sign in …
Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin–A Phase 2 Registry Study
A Khatami, G Sistani, DEK Sutherland… - Current …, 2022 - ingentaconnect.com
Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
[PDF][PDF] Toxicity and Tolerability of 177 Lu-DOTA-TATE PRRT with a Modified Ad-ministered Activity Protocol in NETs of Variable Origin–A Phase 2 Reg-istry Study
A Khatami, G Sistani, DEK Sutherland… - scienceopen.com
Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin-A Phase 2 Registry Study
A Khatami, G Sistani… - Current …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Peptide receptor radionuclide therapy (PRRT) has been recently approved for
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective This study …
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective This study …
[PDF][PDF] Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Ad-ministered Activity Protocol in NETs of Variable Origin–A Phase 2 Reg-istry Study
A Khatami, G Sistani, DEK Sutherland… - researchgate.net
Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …